The burden of disease in seronegative myasthenia gravis: a patient-centered perspective DOI Creative Commons
Sophie Lehnerer, Regina Stegherr, Ulrike Grittner

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 8, 2025

Myasthenia gravis (MG) is an autoimmune disorder primarily caused by autoantibodies against the acetylcholine receptor (AChR). Approximately 15% of MG patients, categorized as seronegative (snMG), lack detectable antibodies. Due to snMG status, there may be a diagnostic delay. Moreover, are limited data on treatment response in comparison AChR-Ab+ patients. This study examines burden disease, response, and quality life patients AChR-ab+ healthy controls. A questionnaire-based survey was conducted collecting sociodemographic clinical including antibody therapy, self-rated disease severity along with standardized assessments such MG-ADL (activities daily living) Short Form Health (SF-36, generic Health-Related Quality Life, HRQoL). HRQoL evaluated through matched-pairs analyses. Participants from general health served control group. Negative binomial regression applied evaluate impact status MG-ADL. Compared (n = 237) were younger at symptom onset [median age 42 (IQR 30.5/53) vs. 51 (31/64) years, p < 0.001] had longer delays. Complete stable remission less frequent (15.9% 27.8%, 0.001), they reported higher (52.8% medium, 9.5% severe 41.9% 8.5% severe, 0.005). scores 5 2/9) 3 (1/6), more employment restrictions (64.4% 49.3%, 0.001). Furthermore, compared controls, showed worse outcomes all domains SF-36. The due delay diagnosis, factors. These findings highlight challenges treating physicians face snMG. There high need for earlier improved tools, inclusion trials address their unique therapeutic challenges. clinicaltrials.gov, identifier NCT03979521. Registered 7 June 2019 (retrospectively registered).

Language: Английский

New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making DOI Creative Commons
Lea Gerischer, Paolo Doksani, Sarah Hoffmann

et al.

BioDrugs, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 27, 2025

Language: Английский

Citations

1
The burden of disease in seronegative myasthenia gravis: a patient-centered perspective DOI Creative Commons
Sophie Lehnerer, Regina Stegherr, Ulrike Grittner

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 8, 2025

Myasthenia gravis (MG) is an autoimmune disorder primarily caused by autoantibodies against the acetylcholine receptor (AChR). Approximately 15% of MG patients, categorized as seronegative (snMG), lack detectable antibodies. Due to snMG status, there may be a diagnostic delay. Moreover, are limited data on treatment response in comparison AChR-Ab+ patients. This study examines burden disease, response, and quality life patients AChR-ab+ healthy controls. A questionnaire-based survey was conducted collecting sociodemographic clinical including antibody therapy, self-rated disease severity along with standardized assessments such MG-ADL (activities daily living) Short Form Health (SF-36, generic Health-Related Quality Life, HRQoL). HRQoL evaluated through matched-pairs analyses. Participants from general health served control group. Negative binomial regression applied evaluate impact status MG-ADL. Compared (n = 237) were younger at symptom onset [median age 42 (IQR 30.5/53) vs. 51 (31/64) years, p < 0.001] had longer delays. Complete stable remission less frequent (15.9% 27.8%, 0.001), they reported higher (52.8% medium, 9.5% severe 41.9% 8.5% severe, 0.005). scores 5 2/9) 3 (1/6), more employment restrictions (64.4% 49.3%, 0.001). Furthermore, compared controls, showed worse outcomes all domains SF-36. The due delay diagnosis, factors. These findings highlight challenges treating physicians face snMG. There high need for earlier improved tools, inclusion trials address their unique therapeutic challenges. clinicaltrials.gov, identifier NCT03979521. Registered 7 June 2019 (retrospectively registered).

Language: Английский

Citations

0